Sugi Predict

Sugi Predict / Compounds / SCHEMBL292378

SCHEMBL292378

SCHEMBL292378

CC[CH]N(CCCC)CCCC

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 3/20 0.33
▸ TSHR P16473 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CA12 O43570 3/20 0.32
▸ CA1 P00915 3/20 0.32
▸ CA9 Q16790 3/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ ALDH2 P05091 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ MMP1 P03956 1/20 0.30
▸ MMP2 P08253 1/20 0.30
▸ MMP3 P08254 1/20 0.30
▸ MMP8 P22894 1/20 0.30
▸ CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10735062 0.92 DNM1 (0.43) DNM1TSHRLMNACA12CA1
SCHEMBL2829809 0.89 DNM1 (0.48) DNM1TSHRLMNACA12CA1
SCHEMBL4392906 0.89 DNM1 (0.48) DNM1TSHRLMNACA12CA1
SCHEMBL3130000 0.89 DNM1 (0.48) DNM1TSHRLMNACA12CA1
SCHEMBL21084368 0.87 CA12 (0.31) CA12CA1CA9CA2
SCHEMBL543212 0.81 CA1 (0.30) CA1
SCHEMBL3027388 0.80 TSHR (0.39) DNM1TSHRLMNACA12CA1
SCHEMBL291241 0.80 TSHR (0.33) DNM1TSHRLMNACA12CA1
SCHEMBL1405684 0.78 TSHR (0.40) DNM1TSHRALDH1A1THRB
SCHEMBL317337 0.76 TSHR (0.44) DNM1TSHRLMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221577-A 2-Phenoxyquinoline derivative, and preparation method and application thereof 湖南中医药大学 2024-06-21 — — CN claimed
CN-113845485-B Amino acid derivative and preparation method and application thereof 湖南中医药大学 2023-03-14 — — CN claimed
US-8778956-B2 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders JANSSEN PHARMACEUTICA NV (BE) 2014-07-15 — — US claimed
EP-2555747-A2 A COMBINATION OF CROSSLINKED CATIONIC POLYMER AND AMPHOLYTIC POLYMER FOR PERSONAL AND HOUSEHOLD APPLICATIONS Lubrizol Advanced Materials, Inc. (US) 2013-02-13 — — EP claimed
EP-1601674-B1 Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders JANSSEN PHARMACEUTICA NV (BE) 2012-08-08 — — EP claimed
JP-4712384-B2 — — 2011-06-29 — — JP claimed
EP-1647555-B1 THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME INST RADIATION MED AMMS PLA (CN) 2011-04-20 — — EP claimed
US-7727965-B2 C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same HAINAN YANGPU NEW & SPECIAL MEDICINE CO., LTD. (CN) 2010-06-01 — — US claimed
US-7582649-B2 Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents JANSSEN PHARMACEUTICA, NV (BE) 2009-09-01 — — US claimed
US-20090124614-A1 HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS BATTISTA KATHLEEN 2009-05-14 — — US claimed
WO-2003059979-A1 ALKYLAMINO OXAMIDES AS LOW ODOR, NON-FUGITIVE CATALYSTS FOR THE PRODUCTION OF POLYURETHANES GENERAL ELECTRIC COMPANY (US) 2003-07-24 — — WO claimed
US-6111045-A YIELDS A VULCANIZED RUBBER SHOWING IMPROVEMENTS IN HEAT BUILD-UP, TENSILE STRENGTH, ABRASION RESISTANCE AND PROCESSABILITY NIPPON ZEON CO. LTD. (JP) 2000-08-29 — — US claimed
EP-0670838-A1 SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS G.D. SEARLE & CO. (US) 1995-09-13 — — EP claimed
WO-1994012500-A1 SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS G.D. SEARLE & CO. (US) 1994-06-09 — — WO claimed
EP-0433805-A1 N-Substituted 3-cyano-4-phenyl-pyrroles BAYER AG (DE) 1991-06-26 — — EP claimed
US-4914122-A CONTROLLING PLANT DISEASES BAYER AKTIENGESELLSCHAFT (DE) 1990-04-03 — — US claimed
EP-0327987-A1 1-Aminomethyl-3-(2-fluoro-3-chlorophenyl)-4-cyano-pyrrole derivatives BAYER AG (DE) 1989-08-16 — — EP claimed
EP-0327977-A1 1-Aminomethyl-3-(2,4-difluor-3-chlorphenyl)-4-cyanopyrroles BAYER AG (DE) 1989-08-16 — — EP claimed
EP-0281731-A2 1-Aminomethyl-3-aryl-4-cyano-pyrroles BAYER AG (DE) 1988-09-14 — — EP claimed
US-4472304-A CARCINOSTATIC NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1984-09-18 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124614-A1 HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS OPRL1, ADRA1D, OPRD1 DNM1 1262/4885TSHR 1300/4885LMNA 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.